Harvoni Tablet, Film Coated
Product Images NDC 61958-1801

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Harvoni (NDC 61958-1801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Harvoni 01)

Chemical structure diagram of the active ingredient ledipasvir and sofosbuvir from Harvoni tablets. The image depicts the molecular framework with various atoms and bonds clearly illustrated.*

FDA Label Image

Chemical Structure (Harvoni 02)

Chemical structure diagram showing the molecular composition of ledipasvir and sofosbuvir, the active ingredients in Harvoni tablets.*

FDA Label Image

Harvoni 02a

An instructional illustration showing a hand holding a tablet strip or blister pack with a scissors icon and dashed line, indicating where to cut or tear the packaging for Harvoni tablets.*

FDA Label Image

Harvoni 02b

An instructional illustration showing a hand holding a rectangular film-coated tablet strip with a perforated section marked by scissors icons, suggesting where to cut. The image includes a bidirectional arrow at the bottom, indicating the motion or separation direction for splitting the strip.*

FDA Label Image

Harvoni 02c

A black and white instructional illustration showing a hand holding a small strip or pouch while another hand uses tweezers to remove a thin tablet or film-coated strip from the packaging. The image appears to demonstrate how to properly extract a tablet or film-coated dosage form from its container, relevant for medications like Harvoni tablets.*

FDA Label Image

Harvoni 02d

FDA Label Image

Harvoni 02e

An instructional diagram showing a person peeling back the top of a small rectangular pouch or strip, with a dotted line and scissors icon indicating where to cut. The illustration focuses on how to open the packaging, with hands demonstrating the action.*

FDA Label Image

Harvoni 02f

An instructional illustration showing hands tearing open a foil packet containing a tablet. The image depicts how to open the packet properly, likely for oral administration of a film-coated tablet such as Harvoni (ledipasvir and sofosbuvir).*

FDA Label Image

Harvoni 02g

An instructional illustration showing a hand pouring granules from a sachet into a bowl containing liquid with a spoon inside, likely demonstrating how to prepare an oral medication dose.*

FDA Label Image

Harvoni 02h

An instructional illustration showing a close-up of a hand holding a strip with a perforated section indicated for cutting. The image likely demonstrates how to open or prepare the strip, such as for a medication strip or single-use packet.*

FDA Label Image

Harvoni 02i

An instructional illustration showing a hand holding a folded package or packet with a perforated edge marked for cutting. The image indicates using scissors to cut along the dotted line and suggests a horizontal motion where the package is stretched or separated along the bottom seam.*

FDA Label Image

Harvoni 02j

An illustration showing a hand holding a film-coated tablet blister pack while a pair of tweezers is used to remove a single tablet from the pack. The image demonstrates proper tablet removal technique, likely for the Harvoni film-coated tablet.*

FDA Label Image

Harvoni 02k

FDA Label Image

Harvoni 02l

An instructional illustration showing fingers peeling and tearing open a small sealed pouch, likely demonstrating how to open the packaging of a tablet or drug product.*

FDA Label Image

Harvoni 02m

An instructional line drawing depicting two hands tearing open a single-use packet, likely for dispensing or accessing a dose of medication. The image suggests how to open a sealed foil or paper pouch containing the drug product.*

FDA Label Image

Harvoni 02n

An illustration showing a person administering oral granules or powder by pouring from a sachet or packet into their mouth. The image focuses on the lower face and hand holding the packet near the open mouth.*

FDA Label Image

Principal Display Panel (28 Tablet Bottle Label)

Label for Harvoni tablets containing 90 mg ledipasvir and 400 mg sofosbuvir. The film-coated tablets come in a package of 28, manufactured for Gilead Sciences, Inc. The label advises storage below 30°C, dispensing in original container, and references a package insert for dosage. The label also includes a pharmacy alert note regarding medicine interactions.*

FDA Label Image

Harvoni 04

Harvoni 45 mg / 200 mg tablets label showing the prescription drug containing ledipasvir and sofosbuvir. The label states each tablet contains 45 mg of ledipasvir and 200 mg of sofosbuvir. It comes in a package of 28 film-coated tablets, manufactured for Gilead Sciences, Inc. The label includes storage instructions, a pharmacist alert box, and mentions it is made in Canada.*

FDA Label Image

Harvoni 05

Label for Harvoni oral pellets with 33.75 mg/150 mg per packet strength of ledipasvir and sofosbuvir. The label shows this is an Rx only drug, includes a warning box advising not to cover the ALERT box with pharmacy label, and references medicines that should not be taken with Harvoni. The Gilead logo appears on the left side.*

FDA Label Image

Harvoni 06

Harvoni (ledipasvir/sofosbuvir) oral pellets with a strength of 45 mg/200 mg per packet. The label indicates it is prescription only and is provided by Gilead Sciences, Inc. The package contains 28 packets and includes a pharmacy alert notice regarding medication interactions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.